Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Treatment patterns and outcomes of primary central nervous system lymphoma treated with high-dose methotrexate with or without autologous stem cell transplantation or whole brain radiation in the rea-world setting

View Full Paper
Ask AI
Bookmark
Share

Authors

YPYifan PangLevine Cancer InstituteCHC. H. W. HorneNational University of IrelandNSNicole SerapinLevine Cancer Institute

Discussion

Loading...

Member takes

Implication

Retrospective study shows high-dose methotrexate improves progression-free survival in non-Hodgkin lymphoma, indicating effectiveness even with delays.

Key Points

  • This research aims to describe treatment patterns and outcomes in patients with primary central nervous system lymphoma.
  • Retrospective study at Levine Cancer Institute and Wake Forest Baptist Comprehensive Cancer Center.
  • Included patients diagnosed with PCNSL and treated with HDMTX-based regimens.
  • Collected data on demographics, comorbidities, treatment patterns, and outcomes.
  • Median overall survival was significantly shorter in non-ASCT patients compared to ASCT recipients.
  • ASCT resulted in 100% progression-free survival for recipients during median follow-up of 20.1 months.
  • Treatment delays did not significantly affect overall or progression-free survival rates.

Cite This Study

Pang et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0behttps://doi.org/10.1182/blood-2025-8064
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative analysis of consolidation strategies after induction chemotherapy in primary central nervous system lymphoma2025
  2. 2Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients2025
  3. 3Clinical Characteristics and Prognosis of Primary Central Nervous System Lymphoma: A Retrospective Analysis2026 · 2 citations
  4. 4Outcomes of primary CNS lymphoma treated with combined immunochemotherapy with whole-brain radiotherapy2025
  5. 5Characterizing second line and beyond therapies for primary central nervous system lymphomas2024